Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
22- 9.2After-hours26.09.03 05:1110-QEarnings#●●●#●●●
Scribe Therapeutics, Inc.
Scribe Therapeutics has filed its quarterly report (Form 10-Q) for the period ended June 30, 2026. As of August 31, 2026, the company had 18,931,680 shares of common stock outstanding.…more
$15.71+1.98%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.2After-hours26.09.03 05:088-KKey event
Scribe Therapeutics, Inc.
Scribe Therapeutics reported a net loss of $6.477 million for the second quarter of 2026 and successfully raised $155.5 million in aggregate gross proceeds through its July IPO and a concurrent private placement to Sanofi. With these funds, the company believes it has sufficient capital to support operations into the first half of 2029, while advancing its lead clinical candidate STX-1150 into Phase 1 trials.…more
$15.71+1.98%vs prev closeView filingShare - 8.3After-hours26.08.04 05:37SCHEDULE 13GOwnership
Scribe Therapeutics, Inc.
RA Capital Management, L.P.와 Peter Kolchinsky, Rajeev Shah, RA Capital Healthcare Fund, L.P.가 Scribe Therapeutics, Inc.의 보통주에 대한 공동 지분 공시를 위해 2026년 8월 3일 공동 신고 계약을 체결했다. 이들은 향후 Schedule 13G 및 13D 보고서를 단일 서류로 통합하여 제출하기로 합의했다.…more
$15.71+1.98%vs prev closeView filingShare
21 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.2After-hours26.09.03 05:10Bullish#●●●
Scribe Therapeutics Misses Q3 Earnings and Revenue Estimates
Scribe Therapeutics reported a Q3 loss of $2.62 per share, significantly missing analyst expectations. Quarterly revenue of $1.918 million also fell short of the consensus estimate of $3.113 million.…more
$15.71+1.98%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.2After-hours26.09.03 05:05
●●●●●●●● ●●●●● ●●●●●●
Scribe Therapeutics announced the initiation of its Phase 1 trial for the LDL-C lowering therapy STX-1150 and the successful completion of its initial public offering. While the company continues to report net losses and declining revenue, it has secured sufficient capital to fund operations through the first half of 2029.…more
$15.71+1.98%vs prev close - 7.27After-hours26.07.28 05:05
●●●●●●●● ●●●●● ●●●●●●
유전자 편집 기술 기업 스크라이브 테라퓨틱스가 IPO를 통해 약 1억 5,551만 달러의 자금을 성공적으로 조달했습니다. 이번 상장에는 사노피의 제3자 배정 유상증자 참여가 포함되어 향후 임상 개발에 탄력이 붙을 전망입니다.…more
$15.71+1.98%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report